SENTARA HEALTH PLANS

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-668-1550</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

<u>For Medicare Members:</u> Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. Additional indications may be covered at the discretion of the health plan.

Botulinum Toxin Injections®, Type A

<u>Drug Requested</u>: Botox[®] (onabotulinumtoxinA) (J0585) – Hyperhidrosis (Medical)

WIEWIBER & PRESCRIBER IN	NFORMATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	Date of Birth:
Prescriber Name:	
	Date:
Phone Number:	
DEA OR NPI #:	
DRUG INFORMATION: Author	orization may be delayed if incomplete.
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
	ICD Code, if applicable:

Cosmetic indications are EXCLUDED

NOTE: In treating adult patients for one or more indications, the maximum cumulative dose should not exceed 400 units, in a 3-month interval. In pediatric patients, the total dose should not exceed the lower of 10 units/kg body weight or 340 units, in a 3-month interval.

Recommended Dosing: 50 units per axilla

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

	ı Me	Member has a diagnosis of Primary Axillary Hyperhidrosis as defined by having:		
		Visible, excessive sweating for at least six (6) months, <u>AND</u> at least two (2) of the following (submit chart notes; check all that apply):		
		☐ Bilateral, symmetric sweating		
		☐ Impairment of daily activities		
		☐ At least one episode per week		
		☐ Onset before 25 years of age		
		□ Positive family history		
		☐ Cessation of focal sweating during sleep		
☐ Member must have adequate trial and failure of <u>BOTH</u> the following therapies within the past six (6) months (verified by chart notes and/or pharmacy paid claims):				
		Topical antiperspirant (e.g., aluminum chloride hexahydrate 20% such as Certain Dri [®] [OTC], Drysol [®] , Hypercare [®] , Xerac [®] AC [OTC])		
		Systemic anticholinergic drug (e.g., glycopyrrolate, oxybutynin, clonidine)		
Medication being provided by (check applicable box(es) below):				
	Phys	sician's office OR Specialty Pharmacy – Proprium Rx		
For u	rgent	t reviews: Practitioner should call Sentara Pre-Authorization Department if they believe a standard		

For urgent reviews: Practitioner should call Sentara Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Use of samples to initiate therapy does not meet step edit/preauthorization criteria. **

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.